MiMedx Group, Inc

MiMedx Group develops and markets regenerative medicine products derived from human placental tissue. The company’s regulatory filings and product development materials explicitly describe animal testing as a core component of its research and development process. In its public disclosures, MiMedx states that its IDE (Investigational Device Exemption) applications to the FDA must be supported by data from “animal and laboratory testing results.” The company further notes that product development involves “[c]ompletion of preclinical laboratory tests, animal studies and formulations studies under the FDA’s Good Laboratory Practice regulations.”

This reliance on animal testing is integral to bringing its medical devices to market. The company’s own documentation cites “initial laboratory and animal testing” as evidence for the strength and biocompatibility of its collagen-based constructs. As a developer of biologic products derived from animal and human sources, MiMedx Group engages in animal testing as a standard practice for regulatory compliance and product safety validation.